Tech Stocks emergin...
Health Care: Drugs
Opexa Therapeutics Inc. (OPXA: NASDAQ)
$1.49 -0.19 | -11.31%
06/18/13 - 04:00 PM ET
Portfolios with OPXA
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Userneed cash
- UserYaYa
- UserHealthCare Dares
- UserBENITRANS CX
Latest OPXA Headlines from TheStreet
- 5 Stocks Poised for Breakouts 06.07.13 | 02:06 pm
- 4 Health Care Stocks Under $10 to Watch 05.31.13 | 02:05 pm
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Rebound Sharply; S&P 500, Nasdaq Rise Over 1% 02.05.13 | 04:02 pm
- Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug 02.05.13 | 10:02 am
- 5 Stocks Poised for Breakouts 10.12.12 | 01:10 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Biotech Stock Mailbag: Best Stocks to Watch in '11 01.07.11 | 07:01 am
- Opexa Therapeutics Reports Third Quarter 2010 Financial Results 11.09.10 | 08:11 am
- Otix Global, Entropic: Volume Movers 09.13.10 | 02:09 pm
Press Releases for OPXA
- Opexa Therapeutics To Present At The 6th Annual European Life Science CEO Forum - Business Wire 03.04.13 | 08:03 am
- Opexa Therapeutics, Inc. Announces Pricing Of Common Stock And Warrant Offering - Business Wire 02.07.13 | 09:02 am
- Opexa Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.07.13 | 08:02 am
- Merck Serono And Opexa Therapeutics Enter Into Option And License Agreement For Development Of Tcelna™ (imilecleucel-T) For Treatment Of Multiple Sclerosis - Business Wire 02.05.13 | 07:02 am
- Opexa Therapeutics Closes Private Note Offering - Business Wire 01.23.13 | 05:01 pm
- Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement - Business Wire 01.15.13 | 08:01 am
- Opexa Therapeutics Announces Reverse Stock Split - Business Wire 12.14.12 | 04:12 pm
- Opexa Therapeutics Reports Third Quarter 2012 Financial Results And Provides Corporate Update - Business Wire 11.14.12 | 08:11 am
- Opexa Receives Clinical Trial Approval From Health Canada For Novel T-Cell Therapy - Business Wire 11.13.12 | 08:11 am
- Opexa Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.12.12 | 03:11 pm
Partner Headlines for OPXA
- Benzinga's Microcap Movers for Friday July 13, 2012 - Benzinga 07.14.12 | 04:07 pm
- A Busy Week for Multiple Sclerosis News - Seeking Alpha 09.26.10 | 08:09 am
